-
2019-nCoV Spike protein RBD (L452Q, F490S)
2019-nCoV Spike protein RBD (L452Q, F490S)
- 中文名称：
- 2019-nCoV Spike protein RBD (L452Q, F490S)
- 英文名称：
- 2019-nCoV Spike protein RBD (L452Q, F490S)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA73341
- 规格：
- 0.01 mg|0.02 mg|0.05 mg|0.1 mg|2x0.1 mg
- 保存建议：
- Store product at -70 degree C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
- 货期：
- 6-8周
- 纯度：
- N/A
- 产品形式：
- Recombinant protein stored in 50mM sodium phosphate, pH7.5, 300mM NaCl, 150mM imidazole.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Recombinant 2019-nCoV Spike protein S1 subunit, RBD (L452Q, F490S)(319-541) was expressed in CHO cells using a C-terminal his tag. The gene accession number is MN908947.
The receptor binding domain (RBD) of SARS-CoV-2 spike glycoprotein can recognize the ACE2 receptor of the host and is an important determining factor of viral entry and neutralization (1). The Lambda variant (VUI-21JUN-01, lineage C.37) carries the mutations L452Q and F490S on its RBD and the mutations manifest resistance to antiviral immunity. In addition, the L452Q mutation further increases the viral infectivity of the virus (2). The Lambda variant was first reported in Peru in August 2020, and since then has spread to most South American countries. As more variants of the virus emerge, it is pivotal to study the transmissibility, virulence, and the possible tendency to escape antibody neutralization of the virus (3).
